Information  X 
Enter a valid email address

Veos PLC (VEO)


Thursday 02 August, 2001

Veos PLC

Regulatory Approval

Veos PLC
2 August 2001

                                PRESS RELEASE

                                   VEOS PLC


London, 2nd August 2001 - Veos PLC, the female healthcare company, today
announced the Canadian regulatory approval of its conception cap application
by the Therapeutic Products Directorate, Medical Devices Bureau. This approval
represents the first step towards marketing the conception cap in Canada.

'Currently Veos is working with the Jones Institute of the Eastern Virginia
Medical School in the US to evaluate products that would comprise the other
pieces of the conception kit,' said Paul Lewakowski, President of Veos USA.
'Once the other pieces of the conception kit are identified and associated
instructions agreed, the conception kit will be made available to the public.
It is very important to have each piece of the kit approved by the appropriate
regulatory agency as a stand-alone product, supported by a full understanding
of the kit's purpose and application from the professional medical community
in each territory.'

'Veos is committed to providing real world solutions to women trying to
control their reproductive futures,' said Paul Lever, Chairman of the Board of
Veos PLC. 'We want to see this product on the market, since we believe couples
may benefit from a conception aid of this nature. Having Canadian approval
along with FDA approval strengthens our position to co-partner while focusing
our resources on our core products in contraception and drug delivery as an
aid to preventing sexually transmitted diseases.'

Peggy Czyzak-Dannenbaum
CEO, Veos PLC                                           020 7960 6066

David Simonson or Clare Maciocia
Merlin Financial Communications                         020 7606 1244


a d v e r t i s e m e n t